We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
No events to show.
Consensus vs. actual, and revenue trend
Rating & price-target changes
Stored first · Google News · Yahoo Finance (English)
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Maintains Target Price $20 富途牛牛
Morgan Stanley Upgrades Hutchmed (China)(HCM.US) to Hold Rating, Cuts Target Price to $13.6 - 富途牛牛
Morgan Stanley Upgrades Hutchmed (China)(HCM.US) to Hold Rating, Cuts Target Price to $13.6 富途牛牛
Morgan Stanley Upgrades Hutchmed (China)(HCM.US) to Hold Rating, Cuts Target Price to $13.6 - Moomoo
Morgan Stanley Upgrades Hutchmed (China)(HCM.US) to Hold Rating, Cuts Target Price to $13.6 Moomoo
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 03. 05. | After market close (AMC) | — | — | — | — | — | Scheduled |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $0.03 | — | — | $305.68M | Reported |
| FY2024 Q2 | 2023. 06. 30. | Time TBD | — | $0.19 | — | — | $532.87M | Reported |
| FY2023 Q2 | 2022. 06. 30. | Time TBD | — | $-0.19 | — | — | $202.05M | Reported |
No research actions to show.
Compare a firm's past rating changes and its actions on other stocks in the same sector.
As of FY2025Q2 · Source: SEC/DART + price data
Filings, earnings, and institutional changes summarized in one paragraph, with source links.
No holdings data to show.
See new positions, full exits, and weight changes.